Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2015', provides an overview of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) Overview 6
Therapeutics Development 7
Pipeline Products for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Overview 7
Pipeline Products for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Comparative Analysis 8
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Therapeutics under Development by Companies 9
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Therapeutics under Investigation by Universities/Institutes 10
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Products under Development by Companies 13
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Products under Investigation by Universities/Institutes 14
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Companies Involved in Therapeutics Development 15
Med Discovery SA 15
Novartis AG 16
SATT Lutech SAS 17
Skinvisible Pharmaceuticals, Inc. 18
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
BPR-277 - Drug Profile 27
Mechanism of Action 27
R&D Progress 27
Drug to Inhibit Serine Proteinase for Netherton Syndrome - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MDPK-67b - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit Kallikrein for Netherton Syndrome - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables

Number of Products under Development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), H2 2015 7
Number of Products under Development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by Med Discovery SA, H2 2015 15
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by Novartis AG, H2 2015 16
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by SATT Lutech SAS, H2 2015 17
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by Skinvisible Pharmaceuticals, Inc., H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 24
Number of Products by Stage and Molecule Type, H2 2015 26